CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $2,509 | $551 | $240 | $395 |
| - Cash | $207 | $20 | $126 | $28 |
| + Debt | $114 | $91 | $52 | $2 |
| Enterprise Value | $2,417 | $621 | $166 | $369 |
| Revenue | $31 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $30 | -$1 | -$1 | -$1 |
| % Margin | 97.8% | – | – | – |
| EBITDA | -$86 | -$92 | -$87 | -$50 |
| % Margin | -275.9% | – | – | – |
| Net Income | -$105 | -$119 | -$93 | -$49 |
| % Margin | -339.1% | – | – | – |
| EPS Diluted | -0.99 | -1.35 | -1.3 | -0.71 |
| % Growth | 26.7% | -3.8% | -83.1% | – |
| Operating Cash Flow | -$73 | -$84 | -$69 | -$45 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$73 | -$84 | -$70 | -$45 |